Comparative Pharmacology
Head-to-head clinical analysis: ASENAPINE MALEATE versus ZYPREXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASENAPINE MALEATE versus ZYPREXA.
ASENAPINE MALEATE vs ZYPREXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asenapine is an atypical antipsychotic with high affinity for serotonin 5-HT2A, 5-HT2C, 5-HT1A, and dopamine D2 receptors. It also antagonizes alpha1/alpha2-adrenergic and histamine H1 receptors, with moderate affinity for D3 and D4 receptors. The therapeutic effect in schizophrenia and bipolar disorder is primarily mediated through combined 5-HT2A and D2 receptor antagonism.
Olanzapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors, with higher affinity for 5-HT2A than D2. It also blocks histamine H1, alpha-1 adrenergic, and muscarinic M1 receptors.
Sublingual: 5-10 mg twice daily; initial dose 5 mg twice daily, max 10 mg twice daily.
5-10 mg orally once daily; may increase by 5 mg/day at intervals of at least 1 week; maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours. Steady-state is achieved within 3 days. The half-life allows for twice-daily dosing.
Terminal elimination half-life ~30 hours (range 21–54 h) in adults, allowing once-daily dosing; steady-state reached in ~5–7 days. Half-life prolonged in elderly, females, and hepatic impairment.
Approximately 50% of the dose is excreted renally, and 40% fecally. After oral administration, about 50% appears in urine (as unchanged drug and metabolites) and 40% in feces.
Primarily hepatic metabolism via CYP1A2 and CYP2D6; ~7% excreted unchanged in urine, ~57% in urine as metabolites, ~30% in feces (mostly metabolites).
Category A/B
Category C
Atypical Antipsychotic
Atypical Antipsychotic